Efficacy and safety of zopiclone and eszopiclone in the treatment of primary and comorbid insomnia

GABA and Sleep: Molecular, Functional and Clinical Aspects

Volumn 9783034602266, Issue , 2010, Pages 413-451

  Najib, Jadwiga S ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052767533     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-0346-0226-6_18     Document Type: Chapter

References (128)

1. Stinson SC (2001) Chiral chemistry. Chem Eng News 79:45-56
2. Food and Drug Administration [FDA] (1992) FDA's policy statement for the development of new stereoisomeric drugs. US Food and Drug Administration [policy document] http://www.fda.gov/cder/guidance/stereo.htm. Fed Reg.22:249. Accessed June 16 2009
3. Agranat I, Caner H (2002) Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 1:753-768
4. Howland RH (2009) Clinical implications of chirality and stereochemistry in psychopharmacology. J Psychosoc Nurs Ment Health Serv 47:17-21
5. Patil PA, Kothekar MA (2006) Development of safer molecules through chirality. Indian J Med Sci 60:427-437
6. Tucker GT (2000) Chiral switches. Lancet 385:1085-1087
7. Davies NM, Teng XW (2003) Importance of chirality in drug therapy and pharmacy profile: implications for psychiatry. Adv Pharm 1:242-252
8. Blanchard JC, Boireau A, Garret C et al (1979) In vitro and in vivo inhibition by zopiclone of benzodiazepine binding to rodent brain receptors. Life Sci 24:2417-2420
9. Blaschke G, Hempel G, Muller WE (1993) Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality 5:419-421
10. Fernandez C, Gimenes F, Baune B et al (1993) Determination of the enantiomers of zopiclone and its two chiral metabolites in urine using an automated coupled achiral-chiral chromatographic system. J Chromatogr 617:271-278
11. Tang K, Chen Y, Liu J (2008) Resolution of zopiclone enantiomers by biphasic recognition chiral extraction. Sep. Purif Technol 62:681-686
12. Gomis DB, Velasco CB, Sanchez IH et al (2009) Optimization by factorial design of a capillary electrophoresis method for the chiral resolution and determination of zopiclone and its synthesis precursor. J Liq Chromatogr Relat Technol 32:2654-2668
13. Patent Storm. US Patent 7456173 - Compositions comprising zopiclone derivatives and methods of making and using the same. Issued on November 25, 2008 with estimated expiration date October 26, 2026. Available at: http://www.patentstorm.us/patents/7456173/fulltext.html. Accessed 1 July 2009
14. World Intellectual Property Organization. (WO/2009/079940) Method for transformation of crystal form of zopiclone. Available at: http://www.wipo.int/pctdb/en/wo.jsp?WO=2009079940. Accessed 1 July 2009
15. Fernandez C, Alet P, Davrinche C et al (2002) Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. J Pharm Pharmacol 54:335-340
16. Fernandez C, Maradeix V, Gimenez F et al (1993) Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 21:1125-1128
17. Cotrel C, Roussel G (2006) US Patent 7, 125, 874 B2, October 24
18. Lunesta [package insert] (2008) Marlborough, Mass: Sepracor February
19. Najib JS (2006) Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 28:491-516
20. Smith AJ, Adler L, Silk J et al (2001) Effect of a-subunit on allosteric modulation of ion channel function in stably expressed human recombinant γ-aminobutyric acid receptors determined using 36Cl ion flux. Mol Pharmacol 59:1108-1118
21. Sanger DJ (2004) The pharmacology and mechanisms of action of new generation nonbenzodiazepine hypnotic agents. CNS Drugs 18(Suppl 1):9-15
22. Mohler H, Burkard WP, Keller HH et al (1981) Benzodiazepine antagonist Ro 15-1788: binding characteristics and interaction with drug-induced changes in dopamine turnover and cerebellar cGMP levels. J Neurochem 37:714-722
23. Carlson JN, Haskew R, Wacker J et al (2001) Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur J Pharmacol 415:181-189
24. European Medicines Agency (EMEA) (2009) Withdrawal assessment report for Lunivia. International non-proprietary name: eszopiclone. Procedure No. EMEA/H/C/00895. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/lunivia/H-895-WAR.pdf. Accessed 26 October 2009
25. Rudolph U, Crestani F, Mohler H (2001) GABA (A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22:188-194
26. A) receptor are different. J Med Chem 51:7243-7252
27. McMahon LR, Jerussi TP, France CP (2003) Stereoselective discriminative stimulus effects of zopiclone in rhesus monkeys. Psychopharmacology 165:222-228
28. Fernandez C, Martin C, Gimenez F et al (1995) Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet 29:431-441
29. Davies M, Newell JG, Derry JM et al (2000) Characterization of the interaction of zopiclone with gamma-aminobutyric acid type A receptors. Mol Pharmacol 58:756-762
30. Serra M, Concas A, Biggio G (1996) Failure of long-term administration of zopiclone and zolpidem to induce tolerance in mice. Neurosci Res Commun 19:169-178
31. Fleck MW (2002) Molecular actions of (S)-desmethylzopiclone (SEP-174559), an anxiolytic metabolite of zopiclone. J Pharmacol Exp Ther 302:612-618
32. Nofzinger EA, Buysse D, Moul D et al (2008) Eszopiclone reverses brain hyperarousal in insomnia: evidence from [18F]-FDG PET. Sleep 31:A232, Supplement
33. Goa KL, Heel RC (1986) Zopiclone - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as a hypnotic. Drugs 32:48-65
34. Leese P, Maier G, Vaickus L et al (2002) Eszopiclone: pharmacokinetic and pharmacodynamic effects of a novel sedative hypnotic after daytime administration in healthy subjects. Sleep 25:A45, Suppl
35. Maier G, Koch P, Caron J et al (2003) Dose proportionality and time to steady-state of eszopiclone in healthy adult volunteers following single and multiple dosing. Pharm Sci 5:M1325
36. Gaillot J, LeRoux Y, Houghton GW et al (1987) Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 10(Suppl 1):7-21
37. Fernandez C, Gimenez F, Thuillier A et al (1999) Stereoselective binding of zopiclone to human plasma proteins. Chirality 11:129-132
38. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem, and zopiclone. Clin Pharmacokinet 43:227-238
39. Wadworth AN, McTavish D (1993) Zopiclone: a review of its pharmacological properties and therapeutic efficacy as a hypnotic. Drugs Aging 3:441-459
40. LeLiboux A, Frydman A, Gaillot J (1987) Simultaneous determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversedphase high-performance liquid chromatography. J Chromatogr 417:151-158
41. Huq F (2007) Molecular modeling analysis of the metabolism of eszopiclone. J Pharmacol Toxicol 2:732-736
42. Viron B, DeMeyer M, LeLiboux A et al (1990) Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg) in patients with severe chronic renal failure. Int Clin Psychopharmacol 5(Suppl 2):95-104
43. Gaillot J, Heusse D, Houghton GW et al (1983) Pharmacokinetics and metabolism of zopiclone. Pharmacology 27(Suppl 2):76-91
44. O'Toole DP, Carlisle RJT, Howard PJ et al (1986) The influence of altered gastric emptying rates on orally administered zopiclone pharmacokinetics. Br J Clin Pharmacol 21:615
45. Wagner J, Wagner ML (2000) Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 4:551-581
46. McGechan A, Wellington K (2005) Ramelteon. CNS Drugs 19:1057-1065
47. Kim YD, Zhuang HY, Tsutsumi M et al (1993) Comparison of the effect of zopiclone and brotizolam on sleep EEG by quantitative evaluation in healthy young women. Sleep 16:655-661
48. Kanno O, Watanabe H, Kazamatsuri H (1993) Effects of zopiclone, flunitrazepam, triazolam and levomepromazine on the transient change in sleep-wake schedule: polygraphic study, and the evaluation of sleep and daytime condition. Prog Neuropsychopharmacol Biol Psychiatry 17:229-239
49. Hemmeter U, Muller WE, Wittchen HU et al (2000) Effect of zopiclone and temazepam on sleep EEG parameters, psychomotor and memory functions in healthy elderly volunteers. Psychopharmacology 147:384-396
50. Parrino L, Fioriti G, Terzano MG (1996) Cyclic alternating pattern (CAP) rate in the polygraphic investigation of classic and novel hypnotic drugs. Eur Psychiatry 11(Suppl 1):15S-19S
51. Zammit GK, McNabb LJ, Caron J et al (2004) Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 20:1979-1991
52. McCall WV, Erman M, Krystal A et al (2006) A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 22:1633-1642
53. Rosenberg R, Caron J, Roth T et al (2005) An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med 6:15-22
54. Xi M, Chase MH (2009) The impact of age on the hypnotic effects of eszopiclone and zolpidem in the guinea pig. Psychopharmacology 205:107-117
55. Georgiev V (2001) (S)-Zopiclone Sepracor. Curr Opin Investig Drugs 2:271-273
56. Anonymous (2005) Eszopiclone. Eszopiclone, Estorra, S-Zopiclone, Zopiclone-Sepracor. Drugs R D 6:111-115
57. European Medicines Agency (2008) Pre-authorisation evaluation of medicines for human use Doc. Ref. EMEA/CHMP/546022/2008. Available at: http://www.emea.europa.eu/pdfs/human/opinion/Lunivia-54602208en.pdf. Accessed on 20 Aug. 2009
58. European Medicines Agency (2008) Pre-authorisation evaluation of medicines for human use Doc. Ref. EMEA/303056/2009. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/lunivia/30305609en.pdf. Accessed on 19 Jul. 2009
59. Sepracor Press Release (2009) Sepracor files patent infringement lawsuit against eszopiclone ANDA filers. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=90106&p=irolnewsArticle&ID=1268262&highlight. Accessed 20 Sep. 2009
60. Giercksky K, Wickstrom E (1980) A dose-response study in situational insomnia with zopiclone, a new tranquilizer. Clin Ther 3:21-27
61. Dehlin O, Rundgren A, Borjesson L et al (1983) Zopiclone to geriatric patients: a parallel double-blind dose-response clinical trial of zopiclone as a hypnotic to geriatric patients: a study in a geriatric hospital. Pharmacology 27:173-178
62. Mamelak M, Scima A, Price V (1982) Effects of zopiclone on the sleep of chronic insomniacs. Int Pharmacopsychiatry 17(Suppl 2):156-164
63. Fleming JAE, Bourgouin J, Hamilton P (1988) A sleep laboratory evaluation of the longterm efficacy of zopiclone. Can J Psychiatry 33:103-107
64. Krystal AD, Walsh JK, Laska E et al (2003) Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26:793-799
65. Roth T, Walsh JK, Krystal A et al (2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6:487-495
66. Walsh J, Krystal A, Amato D et al (2007) Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 30:959-968
67. Scharf M, Erman M, Rosenberg R et al (2005) A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 28:720-727
68. Allain H, Delahaye C, LeCoz F et al (1991) Post-marketing surveillance of zopiclone in insomnia: analysis of 20, 513 cases. Sleep 14:408-413
69. Hair PI, McCormack PL, Curran MP (2008) Eszopiclone a review of its use in the treatment of insomnia. Drugs 68:1415-1434
70. Krystal A, Ancoli-Israel S, McCall WV et al (2008) The safety of eszopiclone in a 12-week study of elderly out-patients with primary insomnia. In: Poster presented at American Society of Consultant Pharmacists (ASCP), New Orleans, LA, 19-22 Nov. 2008
71. Krystal A, Ancoli-Israel S, McCall WV et al (2008) A 12-week study of eszopiclone in elderly out-patients with primary insomnia: effects of treatment discontinuation. Poster presented at: European College of Neuropsychiatry (ECNP) Barcelona, Spain, Aug. 30-Sep. 3 2008
72. Boyle J, Trick L, Johnsen S et al (2008) Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol 23:385-397
73. Neubauer DN (2009) Current and new thinking in the management of comorbid insomnia. Am J Manag Care 15:S24-32, supplement
74. Fava M, McCall W, Krystal A et al (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59:1052-1060
75. Krystal A, Fava M, Rubens R et al (2007) Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 3:48-55
76. Fontaine R, Beaudry P, Le Morvan P (1990) Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol 5:173-183
77. Mizuki Y, Hashimoto M, Tanaka T et al (1983) A new physiological tool for assessing anxiolytic effects in humans: frontal midline theta activity. Psychopharmacology 80:311-314
78. Inanaga K, Tanaka M, Mizuki Y (1982) Prediction of clinical efficacy of zopiclone by utilizing two psychophysiological tools in healthy volunteers. Int Pharmacopsychiatry 17(2):109-115
79. Pollack M, Kinrys G, Krystal A et al (2008) Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 65:551-562
80. Medical News Today (2009). sepracor reports preliminary phase ii study results for SEP-225441 for the treatment of generalized anxiety disorder. Available at: http://www.medicalnewstoday.com/articles/141429.php/trackback. Accessed 16 Aug. 2009
81. Soares CN, Joffe H, Rubens R et al (2006) Eszopiclone in patients with insomnia during perimenopause and early postmenopause. Obstet Gynecol 108:1402-1410
82. Drewes AM, Andreasen A, Jennum P et al (1991) Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 20:288-293
83. Gronblad M, Nykänen J, Konttinen Y et al (1993) Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol 12:186-191
84. Drewes AM, Bjerregard K, Taagholt SJ et al (1998) Zopiclone as night medication in rheumatoid arthritis. Scand J Rheumatol 27:180-187
85. Schnitzer T, Rubens R, Wessel T et al (2006) The effect of eszopiclone 3 mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia. Sleep 29:A238, Suppl
86. Roth T (2009) Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med 10:19-25
87. Powchik P, Cohn M (2001) (S)-Zopiclone: an isomerically pure non-benzodiazepine hypnotic without respiratory depression. Sleep 24:A170, Suppl
88. Rosenberg R, Roach JM, Scharf M et al (2007) A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med 8:464-470
89. Lettieri CJ, Quast TN, Eliasson AH et al (2008) Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospectie, randomized, placebo-controlled trial. Sleep 31:1310-1316
90. Noble S, Langtry HD, Lamb HM (1998) Zopiclone. An update of its pharmacology, clinical efficacy, and tolerability in the treatment of insomnia. Drugs 55:277-302
91. Delahaye C, Ferrand B, Pieddeloup C et al (1990) Post marketing surveillance of zopiclone: interim analysis on the first 10, 000 cases in a clinical study in general practice. Int Clin Psychopharmacol 5(Suppl 2):131-138
92. Dehlin O, Rubin B, Rundgren A (1995) Double-blind comparison of zopiclone and flunitrazepam in elderly insomniac with special focus on residual effects. Curr Med Res Opin 13:317-324
93. Hajak G, Clarenbach P, Fischer W et al (1994) Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam, and placebo. Int Clin Psychopharmacol 9:251-261
94. Doty RL, Treem J, Tourbier I et al (2009) A double-blind study of the influence of eszopiclone on dysgeusia and taste function. Pharmacol Biochem Behav 94:312-318
95. Erman MK, Zammit G, Rubens R et al (2008) A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med 4:229-234
96. Duggal H (2007) New-onset transient hallucinations possibly due to eszopiclone: a case study. Prim Care Companion J Clin Psychiatry 9:468-469
97. Terzano MG, Rossi M, Palomba V et al (2003) New drugs for insomnia. Comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 26:261-282
98. Billiard M, Besset A, deLustrac C et al (1987) Dose-response effects of zopiclone on night sleep and on nighttime and daytime functioning. Sleep 10(Suppl 1):27-34
99. Nicholson AN, Stone BM (1982) Zopiclone: sleep and performance studies in healthy man. Int Pharmacopsychiatry 17(Suppl 2):92-97
100. Broadhurst A, Cushanaghan C (1987) Residual effects of zopiclone. Sleep 10:48-53
101. O'Hanlon JF (1995) Zopiclone's residual effects on psychomotor and information processing skills involved in complex tasks such as car driving: a critical review. Eur Psychiatry 10(Suppl 3):137S-143S
102. Zammit GK (2009) Comparative tolerability of newer agents for insomnia. Drug Saf 32:735-748
103. Gorenstein C, Tavares SM, Gentil V et al (1990) Psychophysiological effects and dose equivalence of zopiclone and triazolam administered to healthy volunteers. Methodological considerations. Braz J Med Biol Res 23:941-951
104. Tariq SH, Pulisetty S (2008) Pharmacotherapy for insomnia. Clin Geriatr Med 24:93-105
105. Conn DK, Madan R (2003) Use of sleep-promoting medications in nursing home residents. Risks versus benefits. Drugs Aging 23:271-287
106. Hajak G (1999) A comparative assessment of the risks and benefits of zopiclone. A review of 15 years' clinical experience. Drug Saf 21:457-469
107. Lader M (1997) Zopiclone: is there any dependence and abuse potential? J Neurol 244(Suppl 1):S18-S22
108. Voderholzer U, Riemann D, Hornyak M et al (2001) A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur Arch Psychiatry Clin Neurosci 251:117-123
109. Begg EJ, Robson RA, Frampton CM et al (1992) A comparison of the efficacy and tolerance of short acting sedatives midazolam and zopiclone. N Z Med J 105:428-429
110. Fleming JA, McClure DJ, Mayes C et al (1990) A comparison of the efficacy, safety, and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol 5(Suppl 2):29-37
111. Dorian P, Sellers EM, Kaplan H et al (1983) Evaluation of zopiclone physical dependence liability in normal volunteers. Pharmacology 27(Suppl 2):228-234
112. Bianchi M, Musch B (1990) Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol 5(Suppl 2):139-145
113. Jones IR, Sullivan G (1998) Physical dependence on zopiclone: case reports. BMJ 316:117
114. Hajak G, Muller WE, Wittchen HU et al (2003) Abuse and dependence potential for the nonbenzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371-1378
115. Cimolai N (2007) Zopiclone. Is it a pharmacologic agent for abuse? Can Fam Physician 53:2124-2129
116. Pat-Horenczyk R, Hacohen D, Herer P et al (1998) The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology 140:450-457
117. Scharf M (2006) Eszopiclone for the treatment of insomnia. Expert Opin Pharmacother 7:345-356
118. Anonymous (2005) Eszopiclone (Lunesta), a new hypnotic. Obstet Gynecol 106:398-401
119. Monti JM, Pandi-Perumal SR (2007) Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat 3:441-453
120. Ngen CC, Hassan R (1990) A double-blind, placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia. Int Clin Psychopharmacol 5:165-171
121. Elie R, Lavoie G, Bourgouin J et al (1990) Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Psychopharmacol 5:279-286
122. Tamminen T, Hansen PP (1987) Chronic administration of zopiclone and nitrazepam in the treatment of insomnia. Sleep 10(Suppl 1):63-72
123. Pecknold J, Wilson R, leMorvan P (1990) Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol 5(Suppl 2):57-67
124. Alderman CP, Gilbert AL (2009) A qualitative investigation of long-term zopiclone use and sleep quality among Vietnam war veterans with PTSD. Ann Pharmacother 43:1576-1582
125. Sikdar S, Ruben SM (1996) Zopiclone abuse among polydrug users (letter). Addiction 91:285-291
126. WHO (2006) World Health Organization - Assessment of zopiclone. In: 34th WHO Expert Committee on Drug Dependence (ECDD). http://www.who.int/medicines/areas/quality-safety/4.6ZopicloneCritReview.pdf. Accessed 1 Jul. 2009
127. Yanagita T (1983) Dependence potential of zopiclone studied in monkeys. Pharmacology 27(Suppl 2):216-227
128. Clee BC, McBride AJ, Sullivan G (1995) Warning about zopiclone misuse (letter). Addiction 91:1389-1390